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Summary
Background Citicoline is approved in some countries for the treatment of acute ischaemic stroke. The drug has shown 
some evidence of eﬃ  cacy in a pooled analysis. We sought to conﬁ rm the eﬃ  cacy of citicoline in a larger trial.
Methods We undertook a randomised, placebo-controlled, sequential trial in patients with moderate-to-severe acute 
ischaemic stroke admitted at university hospitals in Germany, Portugal, and Spain. Using a centralised minimisation 
process, patients were randomly assigned in a 1:1 ratio to receive citicoline or placebo within 24 h after the onset of 
symptoms (1000 mg every 12 h intravenously during the ﬁ rst 3 days and orally thereafter for a total of 6 weeks 
[2×500 mg oral tablets given every 12 h]). All study participants were masked. The primary outcome was recovery at 
90 days measured by a global test combining three measures of success: National Institutes of Health Stroke Scale ≤1, 
modiﬁ ed Rankin score ≤1, and Barthel Index ≥95. Safety endpoints included symptomatic intracranial haemorrhage 
in patients treated with recombinant tissue plasminogen activator, neurological deterioration, and mortality. This trial 
is registered, NCT00331890.
Results 2298 patients were enrolled into the study from Nov 26, 2006, to Oct 27, 2011. 37 centres in Spain, 11 in 
Portugal, and 11 in Germany recruited patients. Of the 2298 patients who gave informed consent and underwent 
randomisation, 1148 were assigned to citicoline and 1150 to placebo. The trial was stopped for futility at the third 
interim analysis on the basis of complete data from 2078 patients. The ﬁ nal randomised analysis was based on data 
for 2298 patients: 1148 in citicoline group and 1150 in placebo group. Global recovery was similar in both groups 
(odds ratio 1·03, 95% CI 0·86–1·25; p=0·364). No signiﬁ cant diﬀ erences were reported in the safety variables nor in 
the rate of adverse events.
Interpretation Under the circumstances of the ICTUS trial, citicoline is not eﬃ  cacious in the treatment of moderate-
to-severe acute ischaemic stroke.
Funding Ferrer Grupo.
Introduction
Stroke remains one of the most devastating diseases, often 
causing death or gross physical impairment or disability.1,2 
In recent years, stroke has been classed as a medical 
emergency and several clinical trials have been done to 
ﬁ nd eﬀ ective therapies. Among pharmacological therapies, 
two possible treatments exist for acute ischaemic stroke: a 
fast and complete recanalisation of the occluded artery, 
and protection of the brain from the ischaemic injury.3 
So far, only thrombolysis with recombinant tissue plas-
minogen activator (rt-PA), administered within the ﬁ rst 
4·5 h after the onset of symptoms, is recommended for the 
treatment of acute ischaemic stroke.4
Recent research suggests that drugs with the potential 
to enhance endogenous brain plasticity and repair could 
reduce acute brain damage and improve functional 
recovery in animal models of stroke, even when they are 
administered several hours after the ischaemic event.5,6 
One of these new drugs, which might combine neuro-
vascular protection and repair eﬀ ects, is citicoline. This 
drug is an exogenous form of cytidine 5ʹ-diphosphate 
choline, which is essential for the biosynthesis of 
membrane phospholipids. Citicoline acts at several levels 
of the ischaemic cascade and a series of brain repair 
eﬀ ects have been reported.7
Citicoline has been extensively studied in clinical 
trials with over 11 000 patients and volunteers who have 
various neurological disorders, including acute ischae-
mic stroke. In all these studies, citicoline had a similar 
safety proﬁ le as compared with placebo.8 Despite 
some post-hoc positive results in subgroups of stroke 
patients,9–11 primary endpoints failed to show eﬃ  cacy. In a 
pooled analysis with individual patient data of random-
ised clinical trials, oral citicoline at doses between 500 mg 
and 2000 mg per day were associated with an odds ratio 
of 1·33 (95% CI 1·10–1·62) in complete functional and 
neurological recovery when compared with placebo in 
patients with moderate-to-severe acute ischaemic 
stroke.12 A further meta-analysis of tabulated data con-
ﬁ rmed these previous results.13
We sought to conﬁ rm the results of the pooled data 
analysis in a large randomised clinical trial based on a 
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previous, fully speciﬁ ed hypothesis and analysis. The 
primary objective of this study was to assess the eﬀ ects of 
citicoline compared with placebo on the recovery of 
patients with moderate-to-severe acute ischaemic stroke 
at 3 months, after having received 2000 mg daily for 
6 weeks.
Methods
Study design and patients
This randomised, multicentre, double-blinded, sequen-
tial, and placebo-controlled study was approved as 
appropriate by local or national institutional review 
boards. Patients were assigned to treatment only after 
they had given informed consent or, for patients who 
were unable to do so, after consent had been obtained 
from an acceptable surrogate.
The trial protocol has been published online. An 
independent data and safety monitoring committee was 
responsible for safety reviews and interim analyses based 
on the primary-endpoint variable. Two independent 
contract research organisations (Cenduit, Durham, NC, 
USA, and Anagram, Barcelona, Spain) were responsible 
for random allocation of patients, gathering and 
monitoring data. An external biostatistical oﬃ  ce 
(Bioclever, Barce lona, Spain) stored and checked the data 
for consistency, then received allocation codes and 
undertook analyses according to the approved plan.
Baseline assessments included a physical examination, 
CT or MRI, and the quantiﬁ cation of any neurological 
deﬁ cit with the use of the National Institutes of Health 
Stroke Scale (NIHSS), a 15-item scale that measures the 
level of neurological impairment. Total scores on the 
NIHSS ranged from 0 to 42, with higher values reﬂ ecting 
more severe cerebral infarcts. Patients were also assessed 
with the NIHSS on days 3 and 7—or at discharge if 
earlier—after treatment started, and then at weeks 6 
and 12. The modiﬁ ed Rankin score (mRs), a measure of 
disability, was used to assess patients on day 7—or at 
discharge if earlier—at weeks 6 and 12. Scores on the mRs 
range from 0 (no symptoms at all) to 6 (death); a score 
of 5 indicates severe disability (ie, the patient is bedridden 
and incontinent and requires constant nursing care and 
attention). Investigators were certiﬁ ed in the use of the 
NIHSS and mRs. During the follow-up period, the Barthel 
index was applied to assess the ability of patients to 
perform activities of daily living on a scale that ranges from 
0 (complete dependence on help with activities of daily 
living) to 100 (independence). This index was scored at 
weeks 1, 6, and 12. The worst value on the three scales was 
assigned to patients who died.
Patients were eligible for enrolment if they were 
18 years of age or older and had an acute ischaemic stroke 
referable to the middle-cerebral-artery territory with 
compatible neuroimaging and onset of symptoms within 
the previous 24 h. Patients had to score at least eight 
points on the baseline NIHSS, with at least two of these 
points from sections ﬁ ve and six (motor), and a prestroke 
mRs of 0 or 1. The time between hospital admission and 
randomisation had to be less than or equal to 12 h and 
the time between randomisation and the administration 
of the ﬁ rst dose had to be less than or equal to 1 h.
All patients received stroke care according to local 
treatment practice, including rt-PA for eligible patients 
presenting within 4·5 h after the onset of the stroke.
This study is registered with ClinicalTrials.gov 
(NCT00331890).
Randomisation and masking
Patients were randomly assigned to receive citicoline or 
placebo for a period of 6 weeks. The randomisation 
process was centralised using an interactive voice 
response system (IVRS), under a minimisation process 
to balance the 1 to 1 ratio between the two groups both 
overall as well as within every category of the baseline 
factors: NIHSS (8–14, 15–22, or ≥23); therapeutic window 
(≤12 h or >12 h); intended use of rt-PA (yes or no); age 
(≤70 or >70 years); and side of stroke (right or left 
Figure 1: Trial proﬁ le
rt-PA=recombinant tissue plasminogen activator. *The intention-to-treat analysis included all patients who 
underwent randomisation in the allocated group and their informed consent was available. †After randomisation, one 
patient in each arm received the alternate treatment. ‡As more than one reason for exclusion from the per-protocol is 
possible, the total number of reasons is greater than the number of excluded patients.
2322 randomised allocations generated
24 excluded
12 randomised allocations
 were erroneously repeated
12 informed consents not
veriﬁed or withdrawn
2298 randomly assigned*
1148 assigned to citicoline 1150 assigned to placebo
8 did not start treatment 2 did not start treatment
2288 started treatment†
1140 included in the safety population 1148 included in the safety population
267 excluded‡
164 poor compliance
64 no scales at visit 5
54 protocol violation
17 time from onset of
symptoms to 
rt-PA >4·5 h
15 not permitted procedure
6 had taken commercial
citicoline
4 changes of assigned kit
294 excluded‡
160 poor compliance
72 no scales at visit 5
42 protocol violation
29 time from onset of
symptoms to 
rt-PA >4·5 h
17 not permitted procedure
11 had taken commercial
citicoline
6 changes of assigned kit
873 included in the per-protocol population 854 included in the per-protocol population
For the protocol see http://www.
thelancet.com/protocol-
reviews/06PRT-3005
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hemisphere). Once a patient was classed as eligible and 
informed consent was obtained, the investigator called 
the IVRS, which registered the patient and provided the 
kit number to be administered.
Ferrer Grupo (Barcelona, Spain) supplied the study 
drug and placebo. Citicoline 2000 mg a day was given to 
patients in the active treatment group in the following 
way: during the ﬁ rst 3 days, 1000 mg was administered 
every 12 h in a 100 mL saline solution bag and infused 
during 30–60 min; from day 4 to the end of the treatment 
period, two 500 mg oral tablets were given every 12 h. In 
patients with swallowing problems, tablets were 
dissolved in 30–60 mL of tepid water and administered 
through a nasogastric tube.
Patients, researchers, caregivers, individuals assessing 
the outcomes, data managers, and members of the trial 
steering committee were masked to group assignment. 
Placebo was identical and indistinguishable to the active 
drug in both formats: ampoules and tablets.
In patients returning drugs, poor treatment com-
pliance was predeﬁ ned as the administration of study 
drug below 80%. Additionally, patients who received less 
than 80% of the intravenous dose when it was not 
followed by immediate oral administration were classed 
as non-compliers. Poor compliance was not a reason for 
study withdrawal.
Procedures
Vital signs were closely monitored for the ﬁ rst 24 h and 
then at each assessment time. No other cardiovascular or 
analytical assessment was needed, due to the proven 
safety proﬁ le of citicoline. A follow-up cerebral CT was 
done when investigators established that baseline CT 
failed to show evidence of infarction.
To establish whether citicoline had any eﬀ ect on 
haemorrhagic transformation after treatment with rt-PA, 
brain imaging was repeated after 24–36 h in patients 
receiving concomitant rt-PA. Additionally, brain imaging 
was repeated when neurological worsening occurred 
within the ﬁ rst week after enrolment. An independent CT 
reading panel of two neuroradiologists (Patricia Cuadras 
and Jaume Capellades; who were unaware of treatment 
assignments and clinical outcome) assessed baseline and 
follow-up brain images of patients treated with rt-PA or 
patients who showed neurological worsening. The pro-
cedures for the assessment of the neuroimaging were pre-
established in the CT-reading-panel guidelines, annexed 
to the protocol. Symptomatic intracerebral haem or rhage 
was deﬁ ned as blood at any site in the brain on the CT 
scan (as assessed by the CT reading panel), causing death 
or an increase in the NIHSS score of 4 or more points. 
Type of haemorrhagic transformation was classiﬁ ed 
according to th e European-Australasian Acute Stroke 
Study (ECASS) deﬁ nition.14 Neurological deterior ation 
was deﬁ ned as an increase of 4 or more points in the 
NIHSS score during the ﬁ rst week. Adverse events and 
causes of mortality were also recorded.
The primary endpoint was recovery at 90 days as 
measured by a global test combining the favourable 
responses from all three outcome scales: Barthel index 
(95–100), mRs (0–1), and NIHSS (0–1), which were 
assessed at week 12. Those three components could be 
interpreted as a multidimensional determination of 
patient retrieval.15 This allows a simultaneous global-test 
analysis16 with a single interpretation as patient recovery. 
A similar approach was used in previous studies.12,17 
Further details have been reported elsewhere.16,18,19
Secondary objectives were the rate of favourable response 
in the single scales (mRs, NIHSS, Barthel index), the 
between-groups comparison of the full distribution of the 
mRs scores, and the absolute diﬀ er ence in the NIHSS 
Citicoline 
(N=1148)
Placebo 
(N=1150)
Age (years) 72·9 (11·8) 72·8 (12·1)
≤70 374 (32·6%) 373 (32·4%)
>70 774 (67·4%) 777 (67·6%)
Sex (female) 560 (48·8%) 596 (51·8%)
Time from stroke onset to 
treatment (h)
6·5 (4·0–12·3) 6·8 (4·0–12·0)
Time from stroke onset to 
randomisation (h)
≤12 911 (79·4%) 916 (79·7%)
>12 237 (20·6%) 234 (20·3%)
NIHSS 15 (11–19) 15 (11–19)
8–14 540 (47·0%) 538 (46·8%)
15–22 552 (48·1%) 556 (48·3%)
>22 56 (4·9%) 56 (4·9%)
rt-PA 532 (46·3%) 532 (46·3%)
Side of stroke—left 519 (45·2%) 532 (46·3%)
Stroke aetiological subtype
Total non-missing 1128 1123
Large-artery atherosclerosis 258 (22·9%) 229 (20·4%)
Small-vessel disease 60 (5·3%) 61 (5·4%)
Cardioembolic 533 (47·3%) 534 (47·6%)
Undetermined cause 250 (22·2%) 271 (24·1%)
Other cause 27 (2·4%) 28 (2·5%)
Missing 20 27
Medical history
High blood pressure 841 (73·3%) 830 (72·2%)
Diabetes mellitus 273 (23·8%) 290 (25·2%)
Ischaemic cardiopathy 200 (17·4%) 188 (16·4%)
Atrial ﬁ brillation 405 (35·3%) 417 (36·3%)
Previous transient ischaemic 
attack
99 (8·6%) 101 (8·8%)
Previous stroke 162 (14·1%) 147 (12·8%)
Current smoker 190 (16·6%) 180 (15·7%)
Excessive consumption of alcohol 
(>40 g per day)
39 (3·4%) 40 (3·5%)
Data are number, number (%), mean (SD), or median (IQR). NIHSS=National 
Institute of Health stroke scale. rt-PA=recombinant tissue plasminogen activator.
Table 1: Baseline characteristics
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between baseline and 3 months. As a post-hoc analysis, 
and in accordance with reviewers’ recommendations, and 
CONSORT guidelines, we up dated the previous tabulated 
meta-analysis for acute ischaemic stroke,13 which deﬁ ned 
success as mRs 0–2.
The safety endpoints included death, serious adverse 
events and non-serious adverse events, vital signs for all 
patients, and follow-up neuroimaging data for patients 
receiving rt-PA or with neurological worsening. Also, we 
assessed citicoline safety and tolerability on the basis of 
the following parameters: blood pressure during the ﬁ rst 
3 days of treatment and week 1 (or discharge), and 
adverse events reported by investigators.
Statistical analysis
Statistical analyses followed the protocol and the 
intention-to-treat principle with no deviations. Analyses 
were fully speciﬁ ed in a statistical analysis plan before 
treatment allocation was provided.
Statistical analyses for primary (global) endpoint were 
based on logistic regression adjusted for minimisation 
factors (baseline NIHSS, therapeutic window, use of 
rt-PA, location of stroke, age, and centre) and sequential 
design. We used a group sequential design using a 
modiﬁ ed version of the triangular test.16 For each 
individual eﬃ  cacy measure (NIHSS, mRs, and Barthel 
index), two summary statistics (Z and V) were calculated. 
The Z statistic measured how much better citicoline was 
than placebo, with a positive value indicating that citicoline 
was better. The V statistic measured how much information 
was contained in the recorded data regarding the 
treatment diﬀ erence. The global test was constructed by 
combining the three separate analyses together to assess 
the combined evidence for the eﬃ  cacy of citicoline.
Secondary (individual) endpoints were adjusted for 
minimisation factors. The distribution of the mRs scores 
was analysed by cumulative ordinal logistic regression, 
which provides a common estimate for the odds ratio 
over any possible cutpoint.
Eﬃ  cacy analyses of the intention-to-treat population 
used the last observation carried forward (LOCF) data 
set. This dataset consists of data recorded or carried 
forward from the most recent visit, either week 6, week 3, 
or at baseline if no data were recorded at week 12 but 
patients were still alive. Any exclusion from this 
population as well as any imputed value to deaths, cross-
in, and drop-outs was decided by the trial steering 
committee before unmasking. Patients who had died 
within 12 weeks (or were lost to follow-up without 
evidence that they were still alive) were recorded as 
failures on all three scales.
Eﬃ  cacy analyses of the per-protocol population inclu-
ded all patients who were randomly assigned, had at least 
one eﬃ  cacy assessment after receiving at least one dose 
of study drug and who met all inclusion criteria and none 
of the exclusion criteria. This sample was made with the 
dataset from observed cases, consisting of only the actual 
data recorded at each visit. This dataset was used to 
investigate the potential for bias in the results due to 
replacement of missing data in the LOCF dataset.
In accordance with recommendations of the reviewers 
of the report and speciﬁ c reporting guidelines,20 we did 
separate post-hoc unadjusted tests for interaction 
Intention-to-treat population Per-protocol population
Citicoline (N=1148) Placebo (N=1150) Odds ratio (95% CI) Citicoline (N=873) Placebo (N=854) Odds ratio (95% CI)
Primary endpoint
Global outcome ·· ·· 1·03 (0·86–1·25)* ·· ·· 1·05 (0·84–1·31)†
Secondary analyses
Shift analyses of mRs ·· ·· 1·02 (0·88–1·19)‡ ·· ·· 1·10 (0·93–1·30)‡
Individual scales
mRs ≤1§ 211 (18·4%) 208 (18·1%) 1·07 (0·85–1·36) 169 (19·4%) 163 (19·2%) 1·04 (0·79–1·36)
NIHSS ≤1§ 264 (23·0%) 260 (22·6%) 1·09 (0·87–1·36) 209 (24·1%) 190 (22·3%) 1·17 (0·91–1·51)
Barthel index ≥95§ 307 (26·7%) 321 (27·9%) 0·95 (0·77–1·17) 250 (28·8%) 246 (28·9%) 1·01 (0·79–1·28)
Percentages represent success for the dichotomised scales. mRs=modied Rankin score. NIHSS=National Institutes of Health stroke scale. *Odds ratio adjusted for the 
sequential design and minimisation factors and centre. †Odds ratio adjusted for minimisation factors. ‡Cumulative ordinal logistic regression for the entire scale distribution 
(adjusted odds ratio). §Unadjusted odds ratio.
Table 2: Odds ratios for primary and secondary endpoints at 90 days
Figure 2: Shift analysis of the modiﬁ ed Rankin score
Common estimate of the odds ratio of improvement over the six possible 
cutpoints are 1·02 (95% CI 0·88–1·19) in the intention-to-treat population (A) and 
1·10 (0·93–1·30) in the per-protocol population (B). mRs=modiﬁ ed Rankin score.
7·1 11·0 11·7 17·2 22·9 8·3 21·8
7·9 10·5 10·3 17·8 25·1 8·6 19·9
Placebo
Citicoline
0 1 2 3 4 5 6
mRs at 12 weeks
A
7·2 12·0 11·2 17·5 22·4 7·3 22·4
8·6 10·8 10·5 19·3 25·4 6·3 19·0
Placebo
Citicoline
B
Proportion of patients in the intention-to-treat population (%)
Proportion of patients in the per-protocol population (%)
See Online for appendix
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between the treatment and each minimisation factor on 
the basis of Cochran’s Q statistic. For the safety analysis, 
patients were classed as treated. The study was designed 
to have an 80% chance of establishing the superiority of 
citicoline if the true log odds ratio (citicoline vs placebo) 
was log (1·26)=0·231, a conser vative value within the 
95% CI obtained in the pooled analysis,12 using a two-
sided 5% signiﬁ cance level. Initially, four interim 
analyses were planned (and a ﬁ nal analysis) to be done 
when the 12-week assessments were available (ie, when 
1000, 1533, 2067, and 2600 patients were recruited). At 
each interim analysis, the data safety and monitoring 
board reviewed unmasked data for patient safety and 
undertook the planned analysis to give one of three 
formal recommendations according to criteria described 
elsewhere.16 After the second interim analysis, which 
included 1532 patients, the trial steering committee 
noted from the masked data that the overall event rate 
was lower than anticipated and that the recruited 
population were 4 years older on average, it had more 
severe stroke (2 points in median NIHSS) and that a 
higher rate of rt-PA had been used. The data and safety 
monitoring board noted with masked data that the 
correlations between the test statistics were higher than 
expected (appendix p 1) and recommended increasing 
the max imum study sample by 750 patients to restore 
power to 80%. If no boundary was reached at the third 
and fourth analyses, then the study would continue to a 
ﬁ fth and ﬁ nal analysis based on 3350 patients. The 
protocol was amended in accordance with this recom-
mendation. Protocol amendment did not include any 
change in eligibility criteria nor clinical outcomes nor 
statistical analysis. On Oct 21, 2011, the data and safety 
monitoring board did the third interim analysis, based 
on complete data for 2078 patients, and found that the 
statistical stopping boundary for futility had been 
crossed. The board recommended that the trial steering 
committee stop recruitment, without explaining the 
reason, and that they ﬁ nish the follow-up for the 
220 already randomly assigned patients. When all the 
recruited patients completed their follow-up, and once 
the database was closed, the data and safety monitoring 
board did the ﬁ nal analysis on 2298 patients and reported 
the results to the trial steering committee.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. Two academic authors (AD and EC) 
Intention-to-treat
analysis
Secondary
Dichotomised
mRs
Barthel index
NIHSS
Ordinal
mRs
Subgroups
rt-PA
Yes
No
Age (years)
≤70
>70
Stroke side
Left
Right
Therapeutic window
>12 h
≤12 h
Baseline NIHSS
8–14
15–22
23–42
Odds ratio
(95% CI)
n (citicoline/placebo) p value
interaction
p value
interaction
Odds ratio
(95% CI)
n (citicoline/placebo)
1·03 (0·86–1·25)
1·07 (0·85–1·36)
0·95 (0·77–1·17)
1·09 (0·87–1·36)
1·02 (0·88–1·19)
0·86 (0·67–1·11)
1·11 (0·85–1·46)
0·79 (0·59–1·05)
1·17 (0·92–1·50)
0·95 (0·72–1·25)
1·03 (0·80–1·32)
0·85 (0·56–1·30)
1·00 (0·81–1·22)
1·08 (0·86–1·35)
0·82 (0·58–1·14)
0·34 (0·07–1·81)
 1148/1150
 1148/1150
 1148/1150
 1148/1150
 1148/1150
 532/532
 616/618
 406/404
 742/746
 519/523
 629/627
 237/234
 911/916
 540/538
  552/556
 56/56
0·0413
..
..
..
..
..
..
..
..
..
..
0·0014
0·5385
0·3243
0·0209
Per-protocol
analysis
Secondary
Dichotomised
mRs
Barthel index
NIHSS
Ordinal
mRs
Subgroups
rt-PA
Yes
No
Age (years)
≤70
>70
Stroke side
Left
Right
Therapeutic window
>12 h
≤12 h
Baseline NIHSS
8–14
15–22
23–42
1·05 (0·84–1·31)
1·04 (0·79–1·36)
1·01 (0·79–1·28)
1·17 (0·91–1·51)
1·10 (0·93–1·30)
0·90 (0·67–1·21)
1·14 (0·84–1·55)
0·72 (0·52–1·00)
1·32 (0·99–1·74)
1·08 (0·78–1·48)
0·99 (0·74–1·32)
1·01 (0·62–1·67)
1·00 (0·79–1·26)
1·17 (0·91–1·51)
0·74 (0·50–1·10)
0·43 (0·08–2·37)
 873/854
 873/854
 873/854
 873/854
 873/854
 394/389
 479/465
 312/301
 561/553
 386/389
 487/465
 174/169
 699/685
 421/403
 409/407
 43/44
0·0956
<0·0001
0·5596
0·9209
0·0043
0·5 0·8 1·0 1·25 2·0
0·5 0·8
Favours placebo Favours citicoline
1·0 1·25 2·0
Favours placebo Favours citicoline
A
B
Figure 3: Forest-plot of all the outcomes
Odds ratios for primary and secondary outcomes and subgroup analyses of 
minimisation factors for main outcome: (A) intention-to-treat population; and 
(B) per-protocol population. Numbers of successes for the three endpoints for 
both groups are shown in table 2, and numbers regarding the ordinal (shift) 
analysis are shown in ﬁ gure 2. Numbers for the subgroup analysis are shown in 
the appendix. mRs=modiﬁ ed Rankin score. rt-PA=recombinant tissue 
plasminogen activator. NIHSS=National Institutes of Health stroke scale. 
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guaranteed the veracity and completeness of the data 
analyses. The trial steering committee had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Patients were enrolled into the study from Nov 26, 2006, to 
Oct 27, 2011. 37 centres in Spain, 11 in Portugal, and 11 in 
Germany recruited patients. Of the 2298 patients who 
gave informed consent and underwent randomisation, 
1148 were assigned to citicoline and 1150 to placebo 
(ﬁ gure 1). All patients were included in the intention-to-
treat population. The treatment was not given to eight 
patients assigned to citicoline and two assigned to placebo, 
in general because of delays in recognising whether or not 
the patient met the eligibility criteria. In no cases did the 
investigators become aware of the study group that was 
assigned to these patients.
The mean age of the trial population was 
72·9 (SD 12·0) years. As expected, both study groups 
were well-balanced with respect to baseline minimisation 
factors, but also with regard to the following factors: 
previous medical history; tobacco and alcohol con-
sumption (table 1); demographics; patient baseline vital 
signs; and serum glucose (data not shown).
A total of 561 (24%) of 2298 patients showed protocol 
deviations (267 citicoline vs 294 placebo; ﬁ gure 1). After 
exclusion of these patients in each group, the resulting 
number of patients were selected for the per-protocol 
analysis.
A total of 859 (75%) of 1148 patients in the citicoline 
group and 838 (73%) of 1150 in the placebo group com-
pleted the 90-day follow-up. 225 (20%) of 1148 patients in 
the citicoline group and 241 (21%) of 1150 in the placebo 
group died before the 90-day follow-up. The worst value 
was imputed, respectively, to three (<1%) of 1148 patients 
in the citicoline group and ten (1%) of 1150 patients in 
the placebo group who were lost to follow-up and could 
not be veriﬁ ed as still alive. LOCF was imputed to 64 (6%) 
of 1148 citicoline patients and 72 (6%) of 1150 placebo 
patients who were alive and had no follow-up scale 
assessment at day 90.
Global recovery at 90 days was similar in both groups. 
The median unbiased estimate of the adjusted odds ratio 
of the primary eﬃ  cacy endpoint was 1·03 (95% CI 
0·86–1·25). The odds ratios were also neutral in the 
subgroups deﬁ ned by the minimisation factors. Similar 
results were reported in the secondary objectives (table 2). 
Shift analysis showed a similar distribution of scores on 
the mRs at 90 days in both groups (ﬁ gure 2). The 
common estimate of the citicoline improvement eﬀ ect 
across any scale cutpoint was odds ratio 1·02 (95% CI 
0·88–1·19). In the analysis of the per-protocol population, 
no beneﬁ t from citicoline over placebo was reported, 
neither in the primary-eﬃ  cacy endpoint nor in the 
secondary endpoints (table 2, ﬁ gure 2). NIHSS score 
improved from baseline in the intention-to-treat popu-
lation (raw mean –1·54 [SD 13·61]) and in the placebo 
group (mean 0·89, SD 14·34), resulting in an eﬀ ect size 
adjusted by minimisation factors of 0·62 (95% CI –0·49 
to 1·73; p=0·27). In the per-protocol population, the raw 
average improvement in the NIHSS score was –2·18 
(SD 13·37) in the citicoline group and –0·91 (14·51) in 
the placebo group, with an eﬀ ect size of 1·26 (95% CI 
–0·01 to 2·53; p=0·051).
Signiﬁ cant results for the heterogeneity of the treat-
ment eﬀ ect among subgroups were reported (ﬁ gure 3). 
The eﬀ ect of citicoline appeared more beneﬁ cial for 
patients older than 70 years of age than for those aged 
70 years or younger (p=0·001); for patients with moderate 
stroke severity (NIHSS <14; p=0·021); and for patients 
not treated with rt-PA (p=0·041). These results were 
similar both in the secondary per-protocol population 
(ﬁ gure 3) and in sensitivity generalised-estimating-
equation analyses (data not shown).
Mortality was comparable between the two groups 
(221 [19%] of 1148 patients in the citicoline group vs 
242 (21%) of 1150 in the placebo group; p=0·31). Adverse 
events were also similar in both groups (4903 total events 
in the citicoline group vs 4923 in the placebo group, 
aﬀ ecting 1064 patients in the citicoline group vs 1080 in 
the placebo group; table 3, appendix pp 2–28). Neurological 
worsening, as deﬁ ned by the protocol, was reported in 
184 (16%) of 1148 patients in the citicoline group and in 
204 (18%) of 1150 patients in the placebo group.
Follow-up CT or MRI examinations were available for 
the CT-reading-panel assessment of 1003 patients from a 
total of 1065 treated with rt-PA (497 in the citicoline and 
506 in the placebo group). Haemorrhagic transformation 
assessed by the CT reading panel occurred in 112 (23%) 
Citicoline 
(N=1140)
Placebo 
(N=1148)
Serious adverse events
Haemorrhagic or ischaemic stroke 59 (5·2%) 52 (4·5%)
Cardiac disorders 45 (3·9%) 39 (3·4%)
Pneumonia 31 (2·7%) 31 (2·7%)
Other adverse events
Cardiac disorders 277 (24·3%) 295 (25·7%)
Pyrexia 258 (22·6%) 254 (22·1%)
Constipation 245 (21·5%) 239 (20·8%)
Urinary tract infections 219 (19·2%) 207 (18·0%)
Headache 154 (13·5%) 160 (13·9%)
Nausea and vomiting symptoms 153 (13·4%) 162 (14·1%)
Agitation 125 (11·0%) 104 (9·1%)
Haemorrhagic transformation stroke 91 (8·0%) 93 (8·1%)
Pneumonia 68 (6·0%) 67 (5·8%)
Hypotension 48 (4·2%) 52 (4·5%)
Ten patients who were randomly assigned were not treated. See appendix for 
every reported adverse event.
Table 3: Most relevant or frequent adverse events reported during 
the study
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of 497 patients receiving rt-PA and citicoline together and 
in 113 (22%) of 506 of those receiving rt-PA and placebo 
(p=0·98). Symptomatic haemorrhagic trans formation 
occurred in 30 (6%) of 497 patients who received citicoline 
and 40 (8%) of 506 patients assigned to placebo (p=0·25). 
Type of haemorrhagic trans formation was comparable 
between groups.
Discussion
The ICTUS trial included a large sample of patients 
with moderate-to-severe acute ischaemic stroke of the 
anterior territory. The randomisation process balanced 
the two groups well with regard to the prognostic 
factors. As the trial was rigorously undertaken and was 
powered to detect an odds ratio of 1·26, we can conclude 
that either there is no treatment eﬀ ect, or there is a 
decreased magnitude of the estimated treatment eﬀ ect 
in previous meta-analyses, or the trial design lacked 
sensitivity to raise such a treatment eﬀ ect. In any case, 
the ICTUS trial has been unable to conﬁ rm the eﬃ  cacy 
of citicoline.
Some other factors could have reduced the sensitivity of 
the ICTUS trial (eg, poor treatment compliance; use of 
concomitant non-protocol drugs, which potentially inter-
fered with treatment response; missing scale values at day 
90; and inclusion criteria protocol violations). However, 
per-protocol analyses of 75% of the total population who 
fulﬁ lled all the protocol criteria obtained similar results.
The pooled meta-analysis of previous randomised trials 
with citicoline showed promising results,12 with an 
increased probability of global recovery at day 90. 
Furthermore, results were also positive in the individual 
mRs and Barthel index scales. The ICTUS trial followed 
a protocol nearly identical to that of the pooled 
meta-analysis, with minimal diﬀ erences in statistical 
analysis. Indeed, the sample rationale and the statistical 
design were built to replicate the results of the meta-
analysis.12 However, none of the beneﬁ ts were conﬁ rmed 
in the ICTUS study. We updated the tabulated data meta-
analysis (ﬁ gure 4) that showed an overall signiﬁ cant eﬀ ect 
of citicoline (odds ratio 1·14, 95% CI 1·00 to 1·30) and a 
signiﬁ cant heterogeneity of eﬀ ects (p=0·0029) between 
the previous studies and the ICTUS trial. These 
discordant results have several possible explanations, 
because there were important diﬀ erences between the 
two study samples.
The trials were done 10 years apart, a period of time in 
which the standard of stroke care has improved 
substantially; patients randomly assigned in the ICTUS 
trial were on average 4 years older, they had more severe 
strokes (median NIHSS 15 [IQR 11–19] in the ICTUS trial 
vs 14 [IQR 10–18] in previous trials), and they were more 
frequently treated with rt-PA (47% in the ICTUS trial vs 
13% in the previous trials). Since only patients with 
NIHSS score of 8 of higher were randomly assigned, 
substantial dilution of eﬀ ect by stroke mimics was 
unlikely. We cannot rule out a ceiling eﬀ ect resulting 
from an already maximal improvement due to rt-PA use. 
The issue of enrolling rt-PA treated patients into stroke 
trials is controversial.23,24 Thus, the conﬂ ict between our 
results and the evidence obtained in previous meta-
analyses12,13 should be interpreted in the context of a lack 
of citicoline eﬀ ect when it is used in addition to the best 
medical treatment (panel). Finally, we cannot rule out that 
treatment up to 24 h after stroke could dilute any beneﬁ cial 
eﬀ ect of the drug. On the other hand, as the updated 
Figure 4: Forest plot for the updated tabulated meta-analysis
Success is deﬁ ned as modiﬁ ed Rankin score of 0, 1, or 2.
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Panel: Research in context
Systematic review
We searched Medline, Embase, and the Cochrane Library for reports published in English 
before May 9, 2012, with the following search terms: “CDP-choline” or “citicoline”; “acute 
ischemic stroke” or “acute cerebral infarction”; and “randomized clinical trial”. We did not 
identify any new, randomised controlled clinical trials of citicoline for the treatment of 
acute ischaemic stroke that were not previously included in the meta-analysis by Saver.13 In 
this meta-analysis, patients receiving citicoline had substantially reduced frequencies of 
death and disability. We have updated this meta-analysis adding ICTUS trial results on 
recovery as measured by a modiﬁ ed Rankin score of 0 to 2. We have not assessed 
haemorrhagic stroke and have not included very old trials, because Saver13 highlighted a 
signiﬁ cant heterogeneity with smaller, lower-quality score trials that tended to show more 
favourable eﬀ ects than larger, higher-quality score trials.
Interpretation
On top of the best treatment, citicoline does not show any clinical improvement but, as 
shown in the updated ﬁ xed-eﬀ ects meta-analysis (ﬁ gure 4), the eﬀ ect of the drug remains 
signiﬁ cant (odds ratio 1·14, 95% CI 1·00–1·30). Heterogeneity coming from the older 
studies suggests that the beneﬁ cial eﬀ ect of citicoline over time was diluted in parallel 
with the improvement of the standard of care of acute ischaemic stroke. The distinct 
eﬀ ects of citicoline in three of ﬁ ve prespeciﬁ ed subgroups cannot be explained by 
selective outcome reporting nor by multiplicity analyses. Further analyses are needed to 
clarify these results.
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meta-analysis is no longer signiﬁ cant, if we exclude the 
more positive and older study, previous meta-analyses 
could have overestimated the treatment eﬀ ect.
Additionally, patients with the most severe strokes and 
large acute ischaemic lesions on CT or MRI were not 
excluded from the trial. Citicoline treatment eﬀ ect might 
have been diluted by the inclusion of patients with 
established large irreversible infarction.
The potential role of these factors in diluting the 
citicoline eﬀ ect could be supported by the results from 
the subgroup analysis. We have obtained some evidence 
of interaction that might suggest a distinct eﬀ ect of 
citicoline in patients older than 70 years of age, in those 
with moderate stroke severity, and in patients not treated 
with rt-PA. However, this interpretation has the weak-
ness of multiplicity analyses and a serious drawback, 
since if we want to accept that citicoline has a positive 
eﬀ ect on those subgroups, we should also be willing to 
accept that it has a negative eﬀ ect in others. In any case, 
those results require further comprehensive analyses.
The prespeciﬁ ed assessment of neuroimaging data 
by the CT reading panel included haemorrhagic trans-
formation in patients treated with rt-PA and in those with 
neurological worsening. In both treatment groups the 
rate of haemorrhagic transformation and symptomatic 
intracerebral haemorrhage was compar able, so we did 
not ﬁ nd any signiﬁ cant citicoline eﬀ ect on the 
haemorrhagic risk of rt-PA. 
The previous pooled analysis12 reported on the overall 
similar safety of citicoline and placebo, yet with a more 
frequent rate of anxiety and leg oedema but lower 
frequency of depression, falling down, and urinary 
incon tinence. However, in the ICTUS trial the num bers 
and types of adverse events and serious adverse events, 
including neurological events, were similar in the 
two groups.
In conclusion, under the circumstances of the ICTUS 
trial, citicoline is safe but is not eﬃ  cacious in the 
treatment of moderate-to-severe acute ischaemic stroke.
Contributors
AD, JAS, JC, ED-T, JF, EM-V, EC, and JJS contributed equally in the 
study design, data analysis, data interpretation, and writing the report. 
AD, JAS, ED-T, JS, TS, VTC, and JM contributed in the collection of 
data, representing the most active centres. All the authors reviewed and 
approved the Article.
International Citicoline Trial on acUte Stroke (ICTUS) investigators
Steering committee AD, Chairman (Hospital Germans Trias i Pujol, 
Badalona, Spain), JAS (Hospital de la Vall d’Hebron, Barcelona, Spain), 
JC (Hospital Clínico Universitario de Santiago, Santiago de Compostela, 
Spain), EC (statistician, UPC, Barcelona, Spain), ED-T (Hospital 
Universitario La Paz. Madrid, Spain), JF (Hospital de Santa Maria, 
Lisbon, Portugal), EM-V (Clínica Universitaria de Navarra, Pamplona, 
Spain), JJS (Ferrer Grupo, Barcelona, Spain).
Data and safety monitoring board
Kennedy R Lees (Glasgow, UK), Steven Warach (Austin, TX, USA), 
John Whitehead (Statistician, Lancaster, UK).
CT reading panel
Patricia Cuadras (Hospital Germans Trias i Pujol de Badalona) and 
Jaume Capellades (Hospital del Mar de Barcelona).
Participating centres
Germany (n=214): Universitätsklinikum Erlangen (46; Martin Köhrmann), 
Universitätsklinikum Leipzig (41; Dietmar Schneider), 
Universitätsklinikum Heidelberg (33; Peter A. Ringleb), 
Universitätsklinikum Münster (27; Martin Ritter), 
Ernst-Moritz-Arndt-Universität Greifswald (26; Christoph Kessler), 
Heinrich-Heine Universität Düsseldorf (12; Sebastian Jander), 
Universitätsklinikum Hamburg-Eppendorf (12; Michael Rosenkranz), 
Johannes Wesling Klinikum Minden (eight; Jörg Glahn), EVK Bielefeld 
(four; Wolf R. Schäbitz), Klinikum Großhadern der Universität München 
(four; Martin Dichgans), Klinikum Ingolstadt (one; Günter Ochs). 
Portugal (391): Hospital Sao Sebastiao. Santa Maria da Feira 
(134; Vitor Tedim Cruz, Carlos Veira, Hans Peter Grebe), Hospitais da 
Universidade de Coimbra (64; Luis Cunha, Gustavo Santo), Hospital de 
Santa Maria. Lisboa (51; Teresa Pinho e Melo, Filipa Falcão), Hospital de 
Vila Real (43; Mario Rui), Hospital Fernando Fonseca. Amadora-Sintra 
(36; Vasco Salgado), Hospital de Santo Antonio. Porto 
(25; Manuel Correia), Hospital de Sao Joao. Porto (20; Elsa Azevedo), 
Centro Hospitalar de Coimbra (nine; Grilo Gonçalves), Centro Hospitalar 
de Setúbal (ﬁ ve; Rui Guerreiro); Hospital de Sao Marcos. Braga (three; 
Joao Fontes), Hospital de Sao Jose. Lisboa (one; Joaquim Candido). 
Spain (1693): Hospital Universitari de la Vall d’Hebron. Barcelona (177; 
José Álvarez Sabín, Joan Montaner, Estevo Santamarina, Olga Maisterra); 
Hospital Universitari de Girona Dr. Josep Trueta (163; Joaquín Serena, 
Mar Castellanos, Yolanda Silva, Cecile van Eendenburg), Hospital 
Universitari Germans Trias i Pujol. Badalona (157; Antoni Dávalos, 
Natalia Pérez de la Ossa, Mónica Millán, Laura Dorado), Hospital General 
de Albacete (146; Tomás Segura, Ana Belén Perona-Moratalla, 
Oscar Ayo-Martín), Hospital Universitario Ramón y Cajal. Madrid 
(119; Jaime Masjuan, Nuria García-Barragán, Araceli Alonso-Cánovas), 
Hospital Universitario La Paz, idiPAZ. Madrid 
(98; Exuperio Díez-Tejedor, Blanca Fuentes), Hospital Universitari de 
Bellvitge (84; Francisco Rubio, Pere Cardona), Hospital Clínico 
Universitario de Santiago. Santiago de Compostela (78; Miguel Blanco, 
Manuel Rodríguez-Yáñez), Hospital de la Santa Creu i Sant Pau. 
Barcelona (76; Josep Lluís Martí-Vilalta, Joan Martí), Hospital del Mar. 
Barcelona (60; Jaume Roquer, Ana Rodriguez Campello), Hospital de 
León (58; Javier Tejada, Luís García-Tuñón), Hospital Universitario de la 
Princesa. Madrid (56; José Vivancos, Álvaro Ximénez-Carrillo), Hospital 
Universitario La Fe. Valencia (53; Aida Lago, Vera Parkhutik), Hospital 
Universitario Gregorio Marañón. Madrid (39; Antonio Gil Nuñez), 
Hospital de Cruces. Bilbao (36; José Larracoechea), Hospital San Pedro 
Alcántara. Cáceres (33; Ignacio Casado), Hospital General Universitario 
de Valencia (31; José Miguel Pons), Hospital Clínico San Carlos. 
Madrid (28; José Antonio Egido), Hospital General Yagüe. Burgos 
(27; José María Trejo), Corporació Sanitària Parc Taulí. Sabadell 
(26; David Cánovas), Hospital de Navarra. Pamplona (25; Jaime Gállego), 
Hospital Clínico de Valladolid (22; Juan Francisco Arenillas), Hospital 
Arnau de Vilanova. Lleida (13; Jordi Sanahuja), Hospital Clínico 
Universitario de Valencia (13; José Miguel Lainez); Hospital de Basurto. 
Bilbao (12; Mª del Mar Freijo), Hospital Clínico Universitario 
‘Lozano Blesa’. Zaragoza (ten; Carlos Tejero), Hospital de Mataró (nine; 
Ernest Palomeras), Hospital Universitario de Getafe (nine; 
Lorenzo Morlan), Hospital Universitario Son Dureta. Palma de Mallorca 
(nine; Carmen Jiménez), Hospital Universitario Virgen Macarena. 
Sevilla (six; Guillermo Izquierdo), Complejo Hospitalario Xeral-Calde. 
Lugo (four; Robustiano Pego), Hospital Universitario Ntra. Sra. 
De Valme. Sevilla (four; Ricardo Fernández-Bolaños), Hospital 
Universitario Marqués de Valdecilla. Santander (four; Mariano Rebollo), 
Hospital do Meixoeiro. Vigo (three; José Luis Maciñeiras), Hospital 
Central de la Defensa. Madrid (two; Antonio Martín), Hospital 
Universitari Sagrat Cor. Barcelona (two; Adrià Arboix), Hospitales 
Universitarios Virgen del Rocío. Sevilla (one; José Ramón Rodríguez).
Conﬂ icts of interest
AD and EC have received consultant fees and honoraria as chairman 
and statistician, respectively, of the trial steering committee; and 
honoraria for giving lectures for Grupo Ferrer. JAS, JC, ED-T, JF, and 
EM-V have received consultant fees and honoraria from Ferrer Grupo as 
members of the trial steering committee. JAS, ED-T, EM-V, JS, TS, and 
JM have received honoraria for giving lectures for Ferrer Grupo. VTC 
Articles
www.thelancet.com   Vol 380   July 28, 2012 357
has received honoraria and travel grants from Ferrer Grupo for 
undertaking the ICTUS trial. JJS is a full-time employee of Ferrer 
Grupo. The authors did not receive any payment for writing or 
contributing to the report.
Acknowledgments
We thank the patients and their families; Matt Elmore for assistance 
with the technical writing; and Konstantina Skaltsa and Jordi Cortés for 
statistical programming.
References
1 Mukherjee D, Patil CG. Epidemiology and the global burden of 
stroke. World Neurosurg 2011; 76 (suppl): S85–90.
2 Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke 
epidemiology: a review of population-based studies of incidence, 
prevalence, and case-fatality in the late 20th century. Lancet Neurol 
2003; 2: 43–53.
3 Labiche LA, Grotta JC. Clinical trials for cytoprotection in stroke. 
NeuroRx 2004; 1: 46–70.
4 Lees KR, Bluhmki E, von Kummer R, et al, and the ECASS, 
ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to 
treatment with intravenous alteplase and outcome in stroke: 
an updated pooled analysis of ECASS, ATLANTIS, NINDS, 
and EPITHET trials. Lancet 2010; 375: 1695–703.
5 Sahota P, Savitz SI. Investigational therapies for ischemic stroke: 
neuroprotection and neurorecovery. Neurotherapeutics 2011; 
8: 434–51.
6 Saver JL. Target brain: neuroprotection and neurorestoration in 
ischemic stroke. Rev Neurol Dis 2010; 7 (suppl 1): S14–21.
7 Gutiérrez-Fernández M, Rodríguez-Frutos B, Fuentes B, et al. 
CDP-choline treatment induces brain plasticity markers 
expression in experimental animal stroke. Neurochem Int 2012; 
60: 310–17.
8 Secades JJ. Citicoline: pharmacological and clinical review, 
2010 update. Rev Neurol 2011; 52 (suppl 2): S1–62.
9 Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA, 
and the Citicoline Stroke Study Group. A randomized 
dose-response trial of citicoline in acute ischemic stroke patients. 
Neurology 1997; 49: 671–78.
10 Clark WM, Williams BJ, Selzer KA, Zweiﬂ er RM, Sabounjian LA, 
Gammans RE. A randomized eﬃ  cacy trial of citicoline in patients 
with acute ischemic stroke. Stroke 1999; 30: 2592–97.
11 Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE, and the 
Citicoline Stroke Study Group. A phase III randomized eﬃ  cacy trial 
of 2000 mg citicoline in acute ischemic stroke patients. Neurology 
2001; 57: 1595–602.
12 Dávalos A, Castillo J, Alvarez-Sabín J, et al. Oral citicoline in acute 
ischemic stroke: an individual patient data pooling analysis of 
clinical trials. Stroke 2002; 33: 2850–57.
13 Saver JL. Citicoline: update on a promising and widely available 
agent for neuroprotection and neurorepair. Rev Neurol Dis 2008; 
5: 167–77.
14 Hacke W, Kaste M, Fieschi C, et al, and the Second 
European-Australasian Acute Stroke Study Investigators. 
Randomised double-blind placebo-controlled trial of thrombolytic 
therapy with intravenous alteplase in acute ischaemic stroke 
(ECASS II). Lancet 1998; 352: 1245–51.
15 Cobo E, Secades JJ, Miras F, et al. Boosting the chances to improve 
stroke treatment. Stroke 2010; 41: e143–50.
16 Bolland K, Whitehead J, Cobo E, Secades JJ. Evaluation of a 
sequential global test of improved recovery following stroke as 
applied to the ICTUS trial of citicoline. Pharm Stat 2009; 8: 136–49.
17 Tissue plasminogen activator for acute ischemic stroke. The 
National Institute of Neurological Disorders and Stroke rt-PA 
Stroke Study Group. N Engl J Med 1995; 333: 1581–87.
18 Whitehead J, Branson M, Todd S. A combined score test for binary 
and ordinal endpoints from clinical trials. Stat Med 2010; 
29: 521–32.
19 Whitehead J. Group sequential trials revisited: simple 
implementation using SAS. Stat Methods Med Res 2011; 20: 635–56.
20 Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics 
in medicine—reporting of subgroup analyses in clinical trials. 
N Engl J Med 2007; 357: 2189–94.
21 Warach S, Pettigrew LC, Dashe JF, et al. Eﬀ ect of citicoline on 
ischemic lesions as measured by diﬀ usion-weighted magnetic 
resonance imaging. Ann Neurol 2000; 48: 713–22.
22 Tazaki Y, Sakai F, Otomo E, et al. Treatment of acute cerebral 
infarction with a choline precursor in a multicenter double-blind 
placebo controlled study. Stroke 1988; 19: 211–16.
23 Röther J. Neuroprotection does not work! Stroke 2008; 39: 523–24.
24 Hermann DM, Chopp M. Promoting brain remodelling and 
plasticity for stroke recovery: therapeutic promise and potential 
pitfalls of clinical translation. Lancet Neurol 2012; 11: 369–80.
